Spero Therapeutics (SPRO) Non-Current Debt (2019 - 2026)

Spero Therapeutics' (SPRO) quarterly Non-Current Debt came in at $91000.0 in Q1 2026, little changed on a QoQ basis from $91000.0 in Q4 2025.

Spero Therapeutics (SPRO) Non-Current Debt (2019 - 2026) Analysis & Trends

Spero Therapeutics (SPRO) has 8 years of Non-Current Debt data on file, last reported at $91000.0 in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $91000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91000.0 (changed N/A YoY) and the FY2025 annual result came in at $91000.0, changed N/A from the prior year.
Non-Current Debt held at $91000.0 in Q1 2026, from $91000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $128000.0 in Q1 2022 to a low of $13000.0 in Q3 2024.
A 5-year average of $77846.2 and a median of $87000.0 in 2023 frame the typical range for Non-Current Debt.
Annual changes were most pronounced in 2023 — Non-Current Debt fell 9.38% — and 2024, when it tumbled 79.03%.
Tracing SPRO's Non-Current Debt over 5 years: stood at $96000.0 in 2022, then slipped by 9.38% to $87000.0 in 2023, then plunged by 85.06% to $13000.0 in 2024, then surged by 600.0% to $91000.0 in 2025, then changed by 0.0% to $91000.0 in 2026.
The last three Non-Current Debt figures came in at $91000.0 (Q1 2026), $91000.0 (Q4 2025), and $13000.0 (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	140.23 Bn	132.38 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.97 Bn	78.97 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.29 Bn	60.11 Bn	1.37 Bn	-
4	Moderna	59.88 Bn	54.74 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.20 Bn	37.11 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	-
7	BioNTech SE	28.69 Bn	10.30 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.16 Bn	26.33 Bn	-	8.96 Bn
10	Spero Therapeutics	71.88 Mn	21.11 Mn	-	91,000.00

Download Data